Mandy Lauw, MD, PhD, recently honored with first-ever Young EHA Award, advocates for bigger roles for early-career clinicians ...

Flatiron Health today announced its presence at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition happening from December 6-9, 2025, in Orlando, Florida. Flatiron's ...

Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

Treatment innovations in advanced lung cancer and melanoma over the past 2 decades have significantly improved OS, but they ...

Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL ...

Working with the same tumor slices that pathologists use to diagnose and guide treatment of patients, however, Carstens can ...

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster presentation highlighting extended follow up analyses examining ...

Lee May, diagnosed with aggressive multiple myeloma at 59, defied odds with cutting-edge treatments at UCSF Health, including ...

Pharmaceutical marketing has often been viewed through the lens of process and execution – campaigns, timelines, approvals.

Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...